Evidence map›Paper›PMID 41659413›Full record

ArticlebioRxiv : the preprint server for biology2026

Selective Immune Silencing by Targeted TGF-β Agonists.

Qinli Sun, Masato Ogishi, Hua Jiang, Alison K Barrett, Hao Yan, Elsa Sola, Jie Zhang, Peng Xiao, Huiyun Lyu, Ahmad Salehi and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qinli SunDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-1220-3388
Masato OgishiInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Hua JiangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Alison K BarrettInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Hao YanDepartment of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA.
Elsa SolaInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Jie ZhangInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Peng XiaoDiabetes Center, University of California, San Francisco, CA, USA.
Huiyun LyuDiabetes Center, University of California, San Francisco, CA, USA.
Ahmad SalehiDonor Network West, San Ramon, CA, USA.
Qizhi TangDiabetes Center, University of California, San Francisco, CA, USA.ORCID 0000-0001-7313-3574
Tobias V LanzInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mark M DavisInstitute for Immunity, Transplantation, and Infection, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Robert S NegrinDepartment of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA.
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9273-0278

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos, Robert S Negrin · 1989 to 2026
$73.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Structure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Specialized Center of Research Excellence on Sex Differences in AutoimmunityU54AR085970 · NIAMS · STANFORD UNIVERSITY · PI PAUL JOSEPH UTZ · 2025 to 2026
$4.4M
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple SclerosisR01AI173189 · NIAID · STANFORD UNIVERSITY · PI Tobias Volker Lanz, William H Robinson · 2023 to 2026
$2.3M
Genetic and immunological dissection of coinhibitory crosstalks between human T cells and cancer cellsK00CA274708 · NCI · STANFORD UNIVERSITY · PI Masato Ogishi · 2024 to 2026
$297k
NCI NIH HHS K00 CA274708NCI NIH HHS P01 CA049605NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI051321NIAID NIH HHS R01 AI173189NIAID NIH HHS U19 AI057229NIAMS NIH HHS U54 AR085970NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Depletion of pathogenic T and B cells is a pillar of first-line therapies for inflammatory, autoimmune, and transplantation-related immunological diseases. However, concerns about adverse events, safety in immunocompromised patients, and disease relapse from incomplete depletion, limit clinical utility. Here, we exploit the immunosuppressive properties of Transforming growth factor beta (TGF-β), through selective "silencing" of T and B cells by a targeted TGF-β mimic agonist derived from Helminths. CD4 and CD8 T cell-targeted TGF-β agonists effectively silence antigen-stimulated T cell activation and expansion in mice and human spleen organoids. A mouse CD4 T cell-targeted TGF-β agonist silences antigen-specific antibody responses by reprogramming pro-inflammatory Th1 and T follicular helper cells into quiescent or regulatory T cell phenotypes

Identifiers

PMID41659413
PMCPMC12879666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.